File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Helicobacter pylori and gastritis: Untangling a complex relationship 27 years on

TitleHelicobacter pylori and gastritis: Untangling a complex relationship 27 years on
Authors
KeywordsGastric cancer
Gastritis
Helicobacter pylori
Intestinal metaplasia
Peptic ulcers
Issue Date2011
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 2011, v. 26 SUPPL. 1, p. 42-45 How to Cite?
AbstractSince its' introduction by Warren and Marshall 27 years ago, Helicobacter pylori (HP) has become the linchpin in our understanding of important gastric conditions including gastritis, intestinal metaplasia (IM), gastric/duodenal ulcers (GU/DU), Mucosal Associated Lymphoid Tumour (MALToma) and gastric cancer. Initially named Campylobacter pyloridis, it was re-named HP when biochemical and genetic characterization of the organism showed that it was not a member of the Campylobacter genus. The finding in 1983 was seminal. It is now recognized that HP is the most common chronic human bacterial infection and it is the most common cause of gastritis. It is strongly implicated in the development of peptic ulcer disease and gastric neoplasms. In the years since its' discovery, much headway has been made in the understanding of this ubiquitous organism that had remained elusive, with much work focused on eradication, in part driven by pharmaceutical research and development. Standard triple therapy emerged to eradicate HP. However, with the emergence of HP resistance, newer regimes have been put forth that include quadruple therapy, sequential therapy and a dizzying array of other combinations bent on eradicating HP. Much less is known about the natural history of HP, the different faces of HP internationally, HP eradication and its effect on gastritis, IM, GU/DU and gastric cancer. This review will address the changing face of HP in 2011. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/139502
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, VPYen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2011-09-23T05:50:43Z-
dc.date.available2011-09-23T05:50:43Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2011, v. 26 SUPPL. 1, p. 42-45en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139502-
dc.description.abstractSince its' introduction by Warren and Marshall 27 years ago, Helicobacter pylori (HP) has become the linchpin in our understanding of important gastric conditions including gastritis, intestinal metaplasia (IM), gastric/duodenal ulcers (GU/DU), Mucosal Associated Lymphoid Tumour (MALToma) and gastric cancer. Initially named Campylobacter pyloridis, it was re-named HP when biochemical and genetic characterization of the organism showed that it was not a member of the Campylobacter genus. The finding in 1983 was seminal. It is now recognized that HP is the most common chronic human bacterial infection and it is the most common cause of gastritis. It is strongly implicated in the development of peptic ulcer disease and gastric neoplasms. In the years since its' discovery, much headway has been made in the understanding of this ubiquitous organism that had remained elusive, with much work focused on eradication, in part driven by pharmaceutical research and development. Standard triple therapy emerged to eradicate HP. However, with the emergence of HP resistance, newer regimes have been put forth that include quadruple therapy, sequential therapy and a dizzying array of other combinations bent on eradicating HP. Much less is known about the natural history of HP, the different faces of HP internationally, HP eradication and its effect on gastritis, IM, GU/DU and gastric cancer. This review will address the changing face of HP in 2011. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectGastric canceren_HK
dc.subjectGastritisen_HK
dc.subjectHelicobacter pylorien_HK
dc.subjectIntestinal metaplasiaen_HK
dc.subjectPeptic ulcersen_HK
dc.subject.meshGastritis - history - microbiology-
dc.subject.meshHelicobacter Infections - complications - drug therapy - history - microbiology-
dc.subject.meshHelicobacter pylori - pathogenicity-
dc.subject.meshPeptic Ulcer - history - microbiology-
dc.subject.meshStomach Neoplasms - history - microbiology-
dc.titleHelicobacter pylori and gastritis: Untangling a complex relationship 27 years onen_HK
dc.typeArticleen_HK
dc.identifier.emailTan, VPY:vpytan@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityTan, VPY=rp01458en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1440-1746.2010.06593.xen_HK
dc.identifier.pmid21199513-
dc.identifier.scopuseid_2-s2.0-78650781806en_HK
dc.identifier.hkuros196571en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78650781806&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issueSUPPL. 1en_HK
dc.identifier.spage42en_HK
dc.identifier.epage45en_HK
dc.identifier.eissn1440-1746-
dc.identifier.isiWOS:000285880400006-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridTan, VPY=24449627600en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats